Photo of Fiona Furlong
 

View Scopus Profile

Fiona Furlong

Dr

  • Room 06.019 - Medical Biology Centre

    United Kingdom

Accepting PhD Students

PhD projects

Open to PhD applications in the field of cancer research, cancer pharmacology, chemoresistance, cell and molecular biology, transcriptomics, biomarker development and drug discovery. Applications should meet the University's English language requirements, secured a source of funding, and who wish to pursue a research project in a relevant research topic.

20002019

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Interests

Receptor Pharmacology

Cancer Pharmacology

Mechanism of Drug Action

Cell Signalling

microRNA

RNA Biomarkers

Cancer Biology

Breast & Ovarian Cancer

Research Statement

Dr Furlong graduated from University College Dublin with a honours degree in Pharmacology and PhD in cell biology.  Prior to joining QUB, Dr Furlong was a recipient of the Irish Cancer Society career development research fellowship and developed novel research on the role of the miR-433 microRNA as a biomarker of chemoresistance in ovarian cancer.  Since then, Dr Furlong has established a program of research in cancer pharmacology and stratified biomarker development. The primary focus of this research is to elucidate the mechanism of action of anti-neoplastic agents.  Current projects include dissecting the molecular pharmacology of the histone deacetylase 6 (HDAC6) protein and the RNA demethylase enzymes.  New and emerging research is focused on developing methods to detect  microRNA as biosensors of disease.  Areas of expertise include researching the mechanism of drug actions and downstream protein signalling in cell models of cancer chemoresistance, cell and molecular biology, biomarker development and profiling microRNA in cells, tissue and plasma. This program of research has led to several high impacting publications and include studies of the miR-433 microRNA in chemoresistant ovarian cancer, IHC biomarker analyses and meta-analyse of the MAD2 protein in ovarian cancer prognosis.  Dr Furlong has received funding from the Irish Cancer Society, the Health Research Board of Ireland, BBSRC and MRC.

Fingerprint

Dive into the research topics where Fiona Furlong is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
  • 38 Similar Profiles

Network

Recent external collaboration on country level. Dive into details by clicking on the dots.
If you made any changes in Pure these will be visible here soon.